Article

Small Peptide Targeting ANP32A as a Novel Strategy For Acute Myeloid Leukemia Therapy

2021-07-28

Abstract excerpt

<h4>Background: </h4> Clinic therapy of acute myeloid leukemia (AML) remains unsatisfactory that urges for development of novel strategy. Recent studies identified ANP32A as a novel biomarker of unfavorable outcome of leukemia, which promoted leukemogenesis by increasing H3 acetylation and the expression of lipid metabolism genes. It is of great significance to investigate whether targeting ANP32A is a novel strat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3599ed52-66e3-5920-958b-6c418912d4de
DOI: 10.21203/rs.3.rs-741617/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 8 closest

Small Peptide Targeting ANP32A as a Novel Strategy For Acute Myeloid Leukemia TherapyDOI 10.21203/rs.3.rs-741617/v1Read

METTL3 affects FLT3-ITD+ Acute Myeloid Leukemia by mediating autophagy by regulating PSMA3-AS1 stabilitySemantic proximity Read

Super enhancer related gene ANP32B promotes the proliferation of acute myeloid leukemia by enhancing MYC through histone acetylationSemantic proximity Read

ANP32B-mediated repression of p53 contributes to maintenance of normal and CML stem cellsSemantic proximity Read

Annexin A3, a Calcium-Dependent Phospholipid-Binding Protein: Implication in CancerSemantic proximity Read

LncRNA-mediated organization of oncogenic chromatin state is a targetable vulnerability in leukemiaSemantic proximity Read

TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTENSemantic proximity Read

Generation of A New Therapeutic D-Peptide That Induces the Differentiation of Acute Myeloid Leukemia Cells Through A TLR-2 Signaling PathwaySemantic proximity Read

An Overview of Targeted Therapies in Acute Myeloid LeukemiaSemantic proximity Read